| 2026-08-04 | Press release | DaVita Inc. 2nd Quarter 2026 Results |
| 2026-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-21 | Press release | DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call |
| 2026-06-08 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-18 | Press release | DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals |
| 2026-05-06 | Press release | DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference |
| 2026-05-05 | Press release | DaVita Inc. 1st Quarter 2026 Results |
| 2026-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-30 | Annual report | Annual report · FY 2025 · Apr 2026 |
| 2026-04-22 | Proxy | Definitive proxy statement |
| 2026-04-20 | Press release | DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call |
| 2026-03-18 | Press release | DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improve |
| 2026-02-24 | Press release | DaVita Inc. to Participate in TD Cowen’s 46th Annual Health Care Conference |
| 2026-02-11 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-03 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-02 | Press release | DaVita Inc. 4th Quarter 2025 Results |
| 2026-02-02 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-21 | Press release | DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call |
| 2025-12-11 | Press release | DaVita Names New Leaders to Accelerate Care Transformation |
| 2025-11-25 | 8-K | Form 8-K, Item 1.01 |
| 2025-11-14 | Press release | DaVita Inc. to Participate in Fireside Chat with Wolfe Research |
| 2025-11-04 | Press release | DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025 |
| 2025-10-29 | Press release | DaVita Inc. 3rd Quarter 2025 Results |
| 2025-10-29 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-29 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-20 | Press release | DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives |
| 2025-10-13 | Press release | DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call |
| 2025-08-27 | Press release | DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care |
| 2025-08-20 | 8-K | Form 8-K, Item 8.01 |
| 2025-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-07-17 | 8-K | Form 8-K, Item 1.01 |
| 2025-06-09 | 8-K | Form 8-K, Item 5.07 |
| 2025-05-23 | 8-K | Form 8-K, Item 1.01 |
| 2025-05-20 | 8-K | Form 8-K, Item 8.01 |
| 2025-05-20 | 8-K | Form 8-K, Item 8.01 |
| 2025-05-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-05-12 | 10-Q | Form 10-Q for the quarter ended Mar 31 |